CD3-ε Inhibitors
Common CD3-ε Inhibitors include, but are not limited to Rapamycin CAS 53123-88-9, Cyclosporin A CAS 59865-13-3, FK-506 CAS 104987-11-3, Mycophenolate mofetil CAS 128794-94-5 and FTY720 CAS 162359-56-0.
CD3-ε inhibitors represent a specialized class of compounds that are meticulously designed to interact with the CD3-ε subunit, one of the crucial components of the CD3 complex found on the surface of T cells. T cells play a pivotal role in the immune system, as they are responsible for identifying and eliminating foreign invaders such as pathogens and cancer cells. The CD3 complex acts as a key signaling hub, facilitating communication between the T cell receptor (TCR) and intracellular signaling pathways upon encountering specific antigens. The TCR recognizes specific antigen fragments presented by major histocompatibility complexes (MHC) on the surface of antigen-presenting cells. Upon successful antigen recognition, the TCR undergoes conformational changes that lead to the recruitment and activation of the CD3 complex, which ultimately triggers a cascade of intracellular events, culminating in T cell activation and immune response initiation. CD3-ε inhibitors are designed with exceptional precision to selectively and reversibly bind to the CD3-ε subunit without interfering with the TCR's direct interaction with antigens or MHC molecules. This characteristic allows them to exert their effects downstream of antigen recognition and TCR engagement. By modulating the CD3-ε subunit's activity, these inhibitors finely tune the strength and duration of TCR signaling, leading to varying outcomes in T cell activation, proliferation, differentiation, and effector functions. Through this targeted modulation of TCR signaling, CD3-ε inhibitors can influence the balance between immune activation and tolerance.
In research settings, these inhibitors have proved to be valuable tools for investigating fundamental immunological processes and understanding the intricacies of immune regulation. It is essential to emphasize that CD3-ε inhibitors represent a distinct chemical class, with diverse molecular structures and properties. Researchers continue to explore and optimize the properties of these inhibitors to enhance their selectivity, potency, and safety. CD3-ε inhibitors hold immense promise as a specialized chemical class that selectively interacts with the CD3-ε subunit of the CD3 complex, influencing T cell activation and function without directly interfering with antigen recognition.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Sirolimus indirectly inhibits T-cell activation by targeting the mTOR (mammalian target of rapamycin) pathway. It forms a complex with FKBP12, and this complex binds to and inhibits mTOR, reducing the response to IL-2 and impairing T-cell proliferation and differentiation. This process ultimately affects CD3-epsilon signaling and downstream T-cell activation. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Cyclosporine A binds to cyclophilins, forming complexes that inhibit calcineurin, a critical phosphatase. This leads to the suppression of IL-2 transcription in T-cells, reducing their activation, proliferation, and cytokine production. CD3-epsilon signaling and T-cell activation pathways are disrupted due to the reduced IL-2 response. | ||||||
FK-506 | 104987-11-3 | sc-24649 sc-24649A | 5 mg 10 mg | $78.00 $151.00 | 9 | |
Like Cyclosporine A, Tacrolimus also inhibits calcineurin through binding to FKBP12, leading to the suppression of IL-2 production and T-cell activation. CD3-epsilon-mediated signaling and downstream immune responses are affected as a consequence. | ||||||
Mycophenolate mofetil | 128794-94-5 | sc-200971 sc-200971A | 20 mg 100 mg | $37.00 $109.00 | 1 | |
Mycophenolate mofetil inhibits inosine monophosphate dehydrogenase (IMPDH), an enzyme involved in de novo guanosine nucleotide synthesis in T-cells. By blocking this pathway, it reduces T-cell proliferation and antibody production. CD3-epsilon signaling and downstream activation are impacted due to the reduced availability of guanosine nucleotides. | ||||||
FTY720 | 162359-56-0 | sc-202161 sc-202161A sc-202161B | 1 mg 5 mg 25 mg | $33.00 $77.00 $120.00 | 14 | |
FTY720 is a sphingosine-1-phosphate receptor modulator. It induces internalization and degradation of S1P1 receptors on T-cells, causing their retention in lymph nodes and preventing their migration to inflammatory sites. | ||||||
Sotrastaurin | 425637-18-9 | sc-474229 sc-474229A | 5 mg 10 mg | $300.00 $540.00 | ||
Sotrastaurin is a protein kinase C (PKC) inhibitor, specifically targeting the PKC-theta isoform involved in T-cell activation. By inhibiting PKC-theta signaling, it interferes with downstream T-cell receptor-mediated activation pathways, including CD3-epsilon signaling, and reduces the immune response. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib is a JAK1/JAK2 inhibitor, and by targeting these enzymes in T-cells, it suppresses the JAK/STAT signaling pathway and downregulates the immune response. CD3-epsilon signaling and downstream activation pathways are affected as a consequence. | ||||||
Baricitinib | 1187594-09-7 | sc-364730 sc-364730A | 5 mg 25 mg | $200.00 $664.00 | ||
Baricitinib is another JAK1/JAK2 inhibitor used to reduce inflammation in autoimmune diseases. By targeting JAK enzymes, it dampens the signaling cascade of inflammatory cytokines and diminishes T-cell activation. CD3-epsilon signaling and downstream T-cell activation are impacted due to the disruption of cytokine-mediated pathways. | ||||||